Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study-Reference-Cited by-同舟云学术

Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study

Published:2024-01-01 Issue:1 Volume:31 Page:61-80
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Kamiya Kiwamu¹,Takei Makoto²,Nagai Toshiyuki¹,Miyoshi Toru³,Ito Hiroshi⁴,Fukumoto Yoshihiro⁵,Obara Hitoshi⁶,Kakuma Tatsuyuki⁶,Sakuma Ichiro⁷,Daida Hiroyuki⁸,Iimuro Satoshi⁹,Shimokawa Hiroaki¹⁰,Kimura Takeshi¹¹,Nagai Ryozo¹²,Anzai Toshihisa¹

Affiliation:

1. Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

2. Department of Cardiology, Saiseikai Central Hospital

3. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

4. Department of General Internal Medicine 3, Kawasaki Medical School

5. Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine

6. Biostatistics Center, Kurume University

7. Caress Sapporo Hokko Memorial Clinic

8. Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine

9. Innovation and Research Support Center, International University of Health and Welfare

10. Graduate School, International University of Health and Welfare

11. Hirakata Kohsai Hospital, Department of Cardiology

12. Jichi Medical University

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/31/1/31_64304/_pdf

Reference41 articles.

1. 1) Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R and Simes R: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278

2. 2) Grundy SM: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med, 1988; 319: 24-33

3. 3) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS and Yeboah J: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-e1143

4. 4) Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL and Cooney MT: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J, 2016; 37: 2999-3058

5. 5) Rader DJ and Hovingh GK: HDL and cardiovascular disease. Lancet, 2014; 384: 618-625

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Residual Cardiovascular Risk Determined through Posthoc Analysis of the REAL-CAD Trial;Journal of Atherosclerosis and Thrombosis;2024-01-01

2. The Worst Combination for Coronary Artery Disease Under Strong-Statin Therapy Is Chronic Kidney Disease and Diabetes　― Non-Lipid Residual Risk Assessment From the REAL-CAD Study ―;Circulation Journal;2023-10-19